About this Medicine article
A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers by Lassen, U. N.; Meulendijks, D.; Siu, L. L.; Karanikas, V.; Mau-Sorensen, M.; Schellens, J. H. M.; Jonker, D. J.; Hansen, A. R.; Simcox, M. E.; Schostack, K. J.; Bottino, D.; Zhong, H.; Roessler, M.; Vega-Harring, S. M.; Jarutat, T.; Geho, D.; Wang, K.; DeMario, M.; Goss, G. D. is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Lassen, U. N.; Meulendijks, D.; Siu, L. L.; Karanikas, V.; Mau-Sorensen, M.; Schellens, J. H. M.; Jonker, D. J.; Hansen, A. R.; Simcox, M. E.; Schostack, K. J.; Bottino, D.; Zhong, H.; Roessler, M.; Vega-Harring, S. M.; Jarutat, T.; Geho, D.; Wang, K.; DeMario, M.; Goss, G. D.
- Publisher
- American Association for Cancer Research; American Association for Cancer Research (AACR) (ISSN 1078-0432)
- Published
- 2015
- Language
- EN
- Field
- Medicine (Health Sciences)